Esperion Therapeutics (ESPR) Equity Average (2013 - 2026)

Esperion Therapeutics has reported Equity Average for 14 years, with the latest figure at -$304.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 25.16% year-over-year to -$304.9 million; the trailing twelve-month figure through Mar 2026 stood at -$304.9 million (up 25.16% YoY), and the FY2025 full-year result was -$345.3 million, up 18.14% from the prior year.
• Equity Average for Q1 2026 stood at -$304.9 million, up from -$376.7 million in the prior quarter.
• The five-year high for Equity Average was -$223.0 million in Q1 2022, with the low at -$442.4 million in Q3 2025.
• Historically, Equity Average has averaged -$352.2 million across 5 years, with a median of -$357.2 million in 2024.
• Annual changes were most pronounced in 2023 — Equity Average plunged 46.52% — and 2026, when it advanced 25.16%.
• Esperion Therapeutics' Equity Average stood at -$308.9 million in 2022, then plunged by 39.99% to -$432.5 million in 2023, then gained by 12.26% to -$379.5 million in 2024, then grew by 0.74% to -$376.7 million in 2025, then climbed by 19.04% to -$304.9 million in 2026.
• The last three Equity Average figures came in at -$304.9 million (Q1 2026), -$376.7 million (Q4 2025), and -$442.4 million (Q3 2025), per Business Quant data.